Clinical Trials
20 trialsNCT07086768 2026-06-03
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT06486883 2026-06-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT07619365 2026-06-02
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT06551220 2026-05-22
HEROIC
Sun Yat-sen University
Recruiting
NCT06663787 2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
NCT07582887 2026-05-13
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Recruiting
NCT06048718 2026-05-08
TUXEDO-4
MedSIR
Phase 2 Active not recruiting
NCT06750484 2026-05-06
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT06172127 2026-04-29
DEMETHER
MedSIR
Phase 2 Active not recruiting
NCT07553390 2026-04-28
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07543536 2026-04-22
MEGA-TACT-BC3
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT05480384 2026-04-21
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Phase 2 Active not recruiting
NCT07340164 2026-04-20
TROY
Yonsei University
Phase 2 Recruiting
NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05034887 2026-04-08
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT07371585 2026-03-27
TOP-REAL
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT05845450 2026-03-12
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting